
Opinion|Videos|May 1, 2026
Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic
This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Episodes in this series

This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Latest CME
Trending on Urology Times
1
Hans Arora, MD, PhD, on improving communication in the OR
2
Radium-223 fails to improve skeletal event-free survival in metastatic RCC
3
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
4
High-Risk BCG-Naive NMIBC: Where Treatment Falls Short Today
5













